Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.

Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.

J Urol. 2017 Feb;197(2S):S200-S207. doi: 10.1016/j.juro.2016.10.073. Epub 2016 Dec 22.

PMID:
28012755
2.

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer.

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP.

Prostate. 2013 Feb 15;73(3):328-35. doi: 10.1002/pros.22573. Epub 2012 Aug 10.

3.

Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.

Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH.

Cancer Prev Res (Phila). 2012 Feb;5(2):290-8. doi: 10.1158/1940-6207.CAPR-11-0306. Epub 2011 Nov 1.

4.

Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.

Algotar AM, Stratton SP, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Thompson PA.

Am J Mens Health. 2011 May;5(3):272-8. doi: 10.1177/1557988310390030.

5.

Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP.

Intern Med J. 2012 Apr;42(4):374-80. doi: 10.1111/j.1445-5994.2011.02473.x.

6.

Dose-dependent effects of selenized yeast on total selenium levels in prostatic tissue of men with prostate cancer.

Algotar AM, Stratton MS, Xu MJ, Dalkin BL, Nagle RB, Hsu CH, Ahmann FR, Clark LC, Stratton SP.

Nutr Cancer. 2011;63(1):1-5. doi: 10.1080/01635581.2010.516476. No abstract available.

7.

No effect of selenium supplementation on serum glucose levels in men with prostate cancer.

Algotar AM, Stratton MS, Stratton SP, Hsu CH, Ahmann FR.

Am J Med. 2010 Aug;123(8):765-8. doi: 10.1016/j.amjmed.2010.02.018.

8.

Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer.

Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR.

Cancer Prev Res (Phila). 2010 Aug;3(8):1035-43. doi: 10.1158/1940-6207.CAPR-09-0143. Epub 2010 Jul 20.

9.

Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP.

Prostate. 2010 Jun 1;70(8):883-8. doi: 10.1002/pros.21122.

10.

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.

Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P, Pantuck A.

Invest New Drugs. 2009 Aug;27(4):379-86. doi: 10.1007/s10637-008-9187-3. Epub 2008 Oct 18.

PMID:
18931824
11.

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI.

J Clin Oncol. 2007 Feb 20;25(6):675-81.

PMID:
17308272
12.

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators.

J Clin Oncol. 2007 Feb 20;25(6):669-74.

PMID:
17308271
13.

Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study.

Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR.

Anticancer Drugs. 2003 Sep;14(8):595-600.

PMID:
14501381
14.

Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study.

Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR.

Anticancer Drugs. 2003 Sep;14(8):589-94.

PMID:
14501380
15.

Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL.

Cancer. 2002 Nov 15;95(10):2136-44.

16.

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.

Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA.

J Clin Oncol. 1998 Apr;16(4):1574-81.

PMID:
9552068
17.

Prostatic asymmetry as a risk factor for prostatic carcinoma: serial prostate-specific antigen monitoring and cancer detection.

Hansen JG Jr, Dalkin BL, Harris CH, Johnson CS, Ahmann FR.

Br J Urol. 1997 Jun;79(6):924-6.

PMID:
9202561
18.
19.

Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.

Harris CH, Dalkin BL, Martin E, Marx PC, Ahmann FR.

J Urol. 1997 May;157(5):1740-3.

PMID:
9112517
20.

Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain.

Krishnamurthy GT, Swailem FM, Srivastava SC, Atkins HL, Simpson LJ, Walsh TK, Ahmann FR, Meinken GE, Shah JH.

J Nucl Med. 1997 Feb;38(2):230-7.

21.
22.

Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma.

Dalkin BL, Ahmann FR, Kopp JB, Catalona WJ, Ratliff TL, Hudson MA, Richie JP, Scardino PT, Flanigan RC, Dekernion JB, et al.

Br J Urol. 1995 Sep;76(3):346-50.

PMID:
7551844
23.

Prostate-specific antigen obtained under optimal conditions determines extracapsular adenocarcinoma of the prostate.

Ehreth JT, Miller JI, McBeath RB, Hansen KK, Ahmann FR, Dalkin BL, Schiff M Jr.

Br J Urol. 1995 Jan;75(1):21-5.

PMID:
7531588
24.

Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.

Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.

J Urol. 1994 Dec;152(6 Pt 1):2037-42.

PMID:
7525995
25.

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC.

J Urol. 1994 Dec;152(6 Pt 1):2031-6.

PMID:
7525994
26.

Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer.

Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.

J Urol. 1994 Nov;152(5 Pt 1):1506-9.

PMID:
7523707
27.

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.

J Urol. 1994 May;151(5):1283-90.

PMID:
7512659
28.
29.

Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.

Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.

Urology. 1993 Oct;42(4):365-74.

PMID:
7692657
30.

Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.

Verdi CJ, Ahmann FR, Schifman RB, Elvick AL, Ahmann ME, Marx PC.

Cancer. 1993 Jun 1;71(11):3625-32.

PMID:
8490911
31.
33.

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.

Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR.

J Urol. 1992 Mar;147(3 Pt 2):956-61.

PMID:
1371568
34.

A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study.

Whitehead RP, Fleming TR, Macdonald JS, Ahmann FR, Garewal HS, Kuebler JP.

Invest New Drugs. 1991 Nov;9(4):345-7.

PMID:
1804811
35.

Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.

Vance RB, Crowley JJ, Macdonald JS, Ahmann FR.

Invest New Drugs. 1991 Feb;9(1):73-5.

PMID:
1851143
36.

Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin.

Kreis W, Ahmann FR, Lesser M, Scott M, Caplan R, Gau T, Vinciguerra V.

J Clin Oncol. 1990 May;8(5):870-4.

PMID:
2139702
37.

Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).

Stephens RL, Goodman P, Crawford ED, Spicer CF, Lowe BA, Ahmann FR, Chapman R, Natale RB.

Invest New Drugs. 1990;8 Suppl 1:S69-71.

38.

The effect of digital rectal examination on serum levels of prostatic-specific antigen.

Brawer MK, Schifman RB, Ahmann FR, Ahmann ME, Coulis KM.

Arch Pathol Lab Med. 1988 Nov;112(11):1110-2.

PMID:
2460065
39.

Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.

Kreis W, Ahmann FR, Jordan VC, de Haan H, Scott M.

Br J Urol. 1988 Oct;62(4):352-4.

PMID:
2973364
40.

The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer.

Ahmann FR, Jones SE, Moon TE.

J Surg Oncol. 1988 Feb;37(2):116-22.

PMID:
3343839
41.

Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared.

Schifman RB, Ahmann FR, Elvick A, Ahmann M, Coulis K, Brawer MK.

Clin Chem. 1987 Nov;33(11):2086-8.

42.

Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.

Ahmann FR, Crawford ED, Kreis W, Levasseur Y.

Cancer Res. 1987 Sep 1;47(17):4736-9.

43.

Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis.

Greenberg BR, Woo L, Veomett IC, Payne CM, Ahmann FR.

Br J Haematol. 1987 Aug;66(4):487-90.

PMID:
3663505
44.

Intracellular adenosine triphosphate as a measure of human tumor cell viability and drug modulated growth.

Ahmann FR, Garewal HS, Schifman R, Celniker A, Rodney S.

In Vitro Cell Dev Biol. 1987 Jul;23(7):474-80.

PMID:
3610945
45.

Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.

Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL.

J Clin Oncol. 1987 Jun;5(6):912-7.

PMID:
2953870
48.

Aminoglutethimide in metastatic adenocarcinoma of the prostate.

Crawford ED, Ahmann FR, Davis MA, Levasseur YJ.

Prog Clin Biol Res. 1987;243A:283-9. No abstract available.

PMID:
3659000
49.

Cytokeratin characterization of human prostatic carcinoma and its derived cell lines.

Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A.

Cancer Res. 1987 Jan 1;47(1):281-6.

50.

Cranial metastases from prostate cancer simulating meningioma: report of two cases and review of the literature.

Lippman SM, Buzaid AC, Iacono RP, Steinbronn DV, Stanisic TH, Rennels MA, Yang PJ, Garewal HS, Ahmann FR.

Neurosurgery. 1986 Nov;19(5):820-3.

PMID:
3785633

Supplemental Content

Loading ...
Support Center